[1]
|
Susanibar-Adaniya, S. and Barta, S.K. (2021) 2021 Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management. American Journal of Hematology, 96, 617-629.
https://doi.org/10.1002/ajh.26151
|
[2]
|
Lenz, G., et al. (2008) Stromal Gene Signatures in Large-B-Cell Lym-phomas. The New England Journal of Medicine, 359, 2313-2323. https://doi.org/10.1056/NEJMoa0802885
|
[3]
|
Poletto, S., et al. (2022) Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma. Cancer Treatment Reviews, 110, Article ID: 102443. https://doi.org/10.1016/j.ctrv.2022.102443
|
[4]
|
Gisselbrecht, C., et al. (2010) Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 28, 4184-4190. https://doi.org/10.1200/JCO.2010.28.1618
|
[5]
|
Westin, J.R., et al. (2023) Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. The New England Journal of Medicine, 389, 148-157. https://doi.org/10.1056/NEJMoa2301665
|
[6]
|
Nastoupil, L.J. and Bartlett, N.L. (2023) Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 41, 903-913. https://doi.org/10.1200/JCO.22.01848
|
[7]
|
Cheson, B.D., et al. (2014) Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32, 3059-3068.
https://doi.org/10.1200/JCO.2013.54.8800
|
[8]
|
Rosenwald, A., et al. (2002) The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine, 346, 1937-1947.
https://doi.org/10.1056/NEJMoa012914
|
[9]
|
Scott, D.W., et al. (2015) Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 33, 2848-2856.
https://doi.org/10.1200/JCO.2014.60.2383
|
[10]
|
Meyer, P.N., et al. (2011) Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab. Journal of Clinical Oncology, 29, 200-207.
https://doi.org/10.1200/JCO.2010.30.0368
|
[11]
|
Muramatsu, M., et al. (2000) Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), A Potential RNA Editing Enzyme. Cell, 102, 553-563.
https://doi.org/10.1016/S0092-8674(00)00078-7
|
[12]
|
Kuppers, R. and Dalla-Favera, R. (2001) Mechanisms of Chromosomal Translocations in B Cell Lymphomas. Oncogene, 20, 5580-5594. https://doi.org/10.1038/sj.onc.1204640
|
[13]
|
Ramiro, A.R., et al. (2004) AID Is Required for C-Myc/IgH Chro-mosome Translocations in Vivo. Cell, 118, 431-438.
https://doi.org/10.1016/j.cell.2004.08.006
|
[14]
|
Pasqualucci, L., et al. (2001) Hypermutation of Multiple Pro-to-Oncogenes in B-Cell Diffuse Large-Cell Lymphomas. Nature, 412, 341-346. https://doi.org/10.1038/35085588
|
[15]
|
International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non- Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994.
https://doi.org/10.1056/NEJM199309303291402
|
[16]
|
Ruppert, A.S., et al. (2020) International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood, 135, 2041-2048. https://doi.org/10.1182/blood.2019002729
|
[17]
|
Neelapu, S.S., et al. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine, 377, 2531-2544. https://doi.org/10.1056/NEJMoa1707447
|
[18]
|
Schuster, S.J., et al. (2017) Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England Journal of Medicine, 377, 2545-2554. https://doi.org/10.1056/NEJMoa1708566
|
[19]
|
Schuster, S.J., et al. (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 380, 45-56. https://doi.org/10.1056/NEJMoa1804980
|
[20]
|
Locke, F.L., et al. (2019) Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial. The Lancet Oncology, 20, 31-42.
https://doi.org/10.1016/S1470-2045(18)30864-7
|
[21]
|
Bukhari, A., et al. (2019) Rapid Relapse of Large B-Cell Lymphoma after CD19 Directed CAR-T-Cell Therapy due to CD-19 Antigen Loss. American Journal of Hematology, 94, E273-E275. https://doi.org/10.1002/ajh.25591
|
[22]
|
Spiegel, J.Y., et al. (2021) CAR T Cells with Dual Targeting of CD19 and CD22 in Adult Patients with Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial. Nature Medicine, 27, 1419-1431.
https://doi.org/10.1038/s41591-021-01436-0
|
[23]
|
Suarez, E.R., et al. (2016) Chimeric Antigen Receptor T Cells Secreting Anti-PD-L1 Antibodies More Effectively Regress Renal Cell Carcinoma in a Humanized Mouse Model. Oncotarget, 7, 34341-34355.
https://doi.org/10.18632/oncotarget.9114
|
[24]
|
Garciaz, S., et al. (2016) Lenalidomide for the Treatment of B-Cell Lymphoma. Expert Opinion on Investigational Drugs, 25, 1103-1116. https://doi.org/10.1080/13543784.2016.1208170
|
[25]
|
Castellino, A., et al. (2018) Lenalidomide Plus R-CHOP21 in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Long-Term Follow-Up Results from a Combined Analysis from Two Phase 2 Trials. Blood Cancer Journal, 8, Article No. 108. https://doi.org/10.1038/s41408-018-0145-9
|
[26]
|
Thieblemont, C., et al. (2017) Lenalidomide Maintenance Com-pared with Placebo in Responding Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 35, 2473-2481. https://doi.org/10.1200/JCO.2017.72.6984
|
[27]
|
Nowakowski, G.S., et al. (2021) ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients with ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 39, 1317-1328. https://doi.org/10.1200/JCO.20.01366
|
[28]
|
Oberic, L., et al. (2021) Subcutaneous Rituximab-MiniCHOP Com-pared with Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of Clinical Oncology, 39, 1203-1213. https://doi.org/10.1200/JCO.20.02666
|
[29]
|
Nowakowski, G.S., et al. (2021) Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in A Randomized Phase II US In-tergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 39, 1329-1338. https://doi.org/10.1200/JCO.20.01375
|
[30]
|
Hernandez-Ilizaliturri, F.J., et al. (2011) Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like than in Germinal Center B-Cell-Like Phenotype. Cancer, 117, 5058-5066. https://doi.org/10.1002/cncr.26135
|
[31]
|
Feldman, T., et al. (2014) Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma. British Journal of Haematology, 166, 77-83.
https://doi.org/10.1111/bjh.12846
|
[32]
|
Martin, A., et al. (2016) Lenalidomide in Combination with R-ESHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 1b Study from GELTAMO Group. British Journal of Haematology, 173, 245-252.
https://doi.org/10.1111/bjh.13945
|
[33]
|
Nuvvula, S., Dahiya, S. and Patel, S.A. (2022) The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 22, 362-372.
https://doi.org/10.1016/j.clml.2021.11.010
|
[34]
|
Crump, M., et al. (2014) Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology, 32, 3490-3496.
https://doi.org/10.1200/JCO.2013.53.9593
|
[35]
|
Chong, E.A., et al. (2021) Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. The New England Journal of Medicine, 384, 673-674. https://doi.org/10.1056/NEJMc2030164
|
[36]
|
Schuster, S.J., et al. (2021) Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 22, 1403-1415. https://doi.org/10.1016/S1470-2045(21)00375-2
|
[37]
|
Locke, F.L., et al. (2022) Axicabtagene Ciloleucel as Se-cond-Line Therapy for Large B-Cell Lymphoma. The New England Journal of Medicine, 386, 640-654. https://doi.org/10.1056/NEJMoa2116133
|
[38]
|
Reddy, A., et al. (2017) Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell, 171, 481-494.e15.
|